Item 2.02. Results of Operations and Financial Condition.
On February 14, 2019, Achaogen, Inc. (the “Company”) issued a press release announcing, among other things, selected preliminary unaudited financial results as of and for the three months ended December 31, 2018. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information contained under Item 2.02 in this Current Report on Form8-K (this “Report”), including Exhibit 99.1, is intended to be “filed” (not “furnished”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and will be deemed to be incorporated by reference in applicable filings under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act.
Item 8.01. Other Events.
On February 14, 2019, the Company issued a press release announcing, among other things, selected preliminary unaudited financial results as of and for the three months ended December 31, 2018 and updates on its commercial and corporate activities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On February 14, 2019, the Company also announced that it recently responded to a Request for Information (“RFI”) regarding antibacterial products with the potential to treat resistant biothreat pathogens. The RFI was solicited by the Assistant Secretary for Preparedness and Response and Biomedical Advanced Research and Development Authority under Project BioShield. The RFI specifically requested information on availabilities and capabilities for procuring, stockpiling and investing in the ongoing development of antibiotic products for commercial use for treatment of multiple biodefense indications, including pneumonic plague and tularemia, for which plazomicin has demonstrated preclinical efficacy.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
